Literature DB >> 9418642

Prognostic factors among 130 patients with osteosarcoma.

L Pochanugool1, T Subhadharaphandou, M Dhanachai, P Hathirat, D Sangthawan, R Pirabul, S Onsanit, N Pornpipatpong.   

Abstract

One hundred thirty patients with high grade osteosarcoma were enrolled in a randomized prospective multidisciplinary treatment that included intraarterial chemotherapy, local irradiation, limb salvage surgery, and prophylactic whole lung irradiation. The patients were evaluated to stage the prognostic factors. In a multivariate analysis, a minimal level of serum lactic acid dehydrogenase less than 300 IU/L showed a significant prognostic value. The history of trauma before diagnosis of disease, local irradiation of the affected site, histologic response to preoperative multidisciplinary therapy, and prophylactic whole lung irradiation were associated with significantly better prognosis in the log rank test. Patient age, site of the primary tumor, presentation of fracture, pathologic subtype, signs and symptoms, serum alkaline phosphatase level, and erythrocyte sedimentation rate were not found to be prognostic factors. The 9-year survival rate of the whole group was 55%.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9418642

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  15 in total

1.  Diffuse pleural metastases of osteosarcoma detected by bone scan.

Authors:  André Marcondes Braga Ribeiro; Eduardo Nobrega Pereira Lima; Daniel Habib Issa Lima
Journal:  World J Nucl Med       Date:  2020-08-22

2.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.

Authors:  Jian Chen; Meng-xiong Sun; Ying-qi Hua; Zheng-dong Cai
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-31       Impact factor: 4.553

3.  The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter.

Authors:  I Sulzbacher; P Birner; K Trieb; E Pichlbauer; S Lang
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

4.  Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.

Authors:  Seong-Hwan Moon; Kyoo-Ho Shin; Jin-Suck Suh; Woo-Ick Yang; Jae-Keong Noh; Soo-Bong Hahn
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

5.  The impact of pathological fractures on therapy outcome in patients with primary malignant bone tumours.

Authors:  Babak Moradi; Anita Zahlten-Hinguranage; Burkhard Lehner; Felix Zeifang
Journal:  Int Orthop       Date:  2009-12-13       Impact factor: 3.075

6.  Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns.

Authors:  L C de Sá Rodrigues; K E Holmes; V Thompson; C M Piskun; S E Lana; M A Newton; T J Stein
Journal:  Vet Comp Oncol       Date:  2015-02-03       Impact factor: 2.613

7.  Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.

Authors:  Enrique González-Billalabeitia; Ricardo Hitt; Jesús Fernández; Esther Conde; Francisco Martínez-Tello; Rafael Enríquez de Salamanca; Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

Review 8.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

9.  Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture.

Authors:  Ke Yin; Qiande Liao; DA Zhong; Jie Ding; Bing Niu; Qiupping Long; Dengfeng Ding
Journal:  Exp Ther Med       Date:  2012-08-28       Impact factor: 2.447

10.  High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China.

Authors:  Ju Han; Bicheng Yong; Canqiao Luo; Pingxian Tan; Tingsheng Peng; Jingnan Shen
Journal:  World J Surg Oncol       Date:  2012-02-15       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.